Abstract
Alzheimer's disease (AD) is a complex neurodegenerative ailment, which demands the use of multifunctional agents for its therapy. Currently, FDA-approved drugs for AD are only palliative. The current research focused on adding a flavone nucleus to the amino group of the acridine nucleus to provide it with Monoamine oxidase (MAO)-B inhibitory properties. Method: We designed and synthesized ten flavone substituted acridine derivatives and evaluated for Invitro MAO B inhibitory activity. Molecular modeling studies were conducted in AutoDock Vina with hMAO B (PDB ID: 2V60). Compounds exhibited MAO B inhibition with IC50 values in 3.24 µM to 9.48 µM concentration. Compounds AF6 and AF14 showed the highest activity with an IC50 value of 3.24 µM for MAO B. The results highlighted the MAO B inhibitory effect of the novel Acridine-Flavone hybrids and they can be promising multitarget directed ligands for AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
